finder.com

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lantern Pharma stock

Own Lantern Pharma stock in just a few minutes.

Avatar
Jing Jun Ma
Fact checked

Lantern Pharma Inc is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Lantern Pharma employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Lantern Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LTRN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

What's in this guide?

  1. LTRN shares summary
  2. Compare share dealing platforms
  3. Is LTRN stock a buy or sell?
  4. Stock performance over time
  5. Can I short LTRN shares?
  6. Lantern Pharma's financials
  7. Does Lantern Pharma pay a dividend?
  8. Other common questions

Lantern Pharma share price

Use our graph to track the performance of LTRN stocks over time.

Lantern Pharma shares at a glance

Information last updated 2021-04-29.
52-week range$10.40 - $23.50
50-day moving average $17.87
200-day moving average $17.17
Wall St. target price$28.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Buy Lantern Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Go to site
More Info
Robinhood
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Go to site
More Info
Interactive Brokers
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Go to site
More Info
Webull
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Go to site
More Info
Public
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
Go to site
More Info
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lantern Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lantern Pharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantern Pharma financials

Gross profit TTM $0
Return on assets TTM -33.89%
Return on equity TTM -57.24%
Profit margin 0%
Book value N/A
Market capitalisation $177.3 million

TTM: trailing 12 months

Shorting Lantern Pharma shares

There are currently 231,466 Lantern Pharma shares held short by investors – that's known as Lantern Pharma's "short interest". This figure is 1.5% up from 227,999 last month.

There are a few different ways that this level of interest in shorting Lantern Pharma shares can be evaluated.

Lantern Pharma's "short interest ratio" (SIR)

Lantern Pharma's "short interest ratio" (SIR) is the quantity of Lantern Pharma shares currently shorted divided by the average quantity of Lantern Pharma shares traded daily (recently around 140282.42424242). Lantern Pharma's SIR currently stands at 1.65. In other words for every 100,000 Lantern Pharma shares traded daily on the market, roughly 1650 shares are currently held short.

However Lantern Pharma's short interest can also be evaluated against the total number of Lantern Pharma shares, or, against the total number of tradable Lantern Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantern Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lantern Pharma shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable Lantern Pharma shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lantern Pharma.

Find out more about how you can short Lantern Pharma stock.

Lantern Pharma share dividends

We're not expecting Lantern Pharma to pay a dividend over the next 12 months.

Lantern Pharma overview

Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. .

  1. Technical analysis graphic from TradingView, https://uk.tradingview.com Stock prices and other date from EOD Historical Data

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site